MedTrace Logo

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

NCT06265545 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 458

Last updated 2026-08-07

No results posted yet for this study

Summary

To study the optimal therapeutic strategies for salvage treatment of refractory/relapsed AML, and to clarify the effectiveness and safety of various salvage treatment options. A prospective, multicenter, platform-type study was conducted to explore the overall response rate, tolerability, and survival of patients with R/R AML with different treatment regimens.

Conditions

  • AML
  • Refractory
  • Relapsed

Interventions

DRUG

Ivosidenib

in arm 1

DRUG

Venetoclax

in arms 2-5

DRUG

Gilteritinib

in arm 2

DRUG

Homoharringtonine

in arms 4 and 7

DRUG

Cytarabine

in arms 3 and 7

DRUG

Daunorubicin/ Idarubicin /Mitoxantrone

in arms 3 and 7

DRUG

Azacitidine

in arms 1，2 , 5 and 8

DRUG

Lisaftoclax

in arms 7 and 8

DRUG

PI3K inhibitors, histone deacetylase inhibitors, selinexor, novel liposomal drugs, and others

in arm 6

Sponsors & Collaborators

  • Institute of Hematology & Blood Diseases Hospital, China

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-22
Primary Completion
2028-01-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06265545 on ClinicalTrials.gov